Search Results

Your search for Novartis in News Releases returned 10 results

News Releases

• Jun 04, 2013, 08:00 ET

  TV Host Phil Keoghan and Novartis team up to inspire people with MS through innovative tandem cycling campaign

  

  Phil Keoghan, host of "The Amazing Race" and founder of No Opportunity Wasted (NOW), joins Novartis Pharmaceuticals Corporation for the third year to raise awareness of multiple sclerosis (MS) through a unique campaign, called Together in MS. The campaign helps show—through participation and...

  More news about: Novartis Pharmaceuticals Corporation

• Jun 03, 2013, 11:37 ET

  Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer

   Novartis today announced data on its investigational compound LDK378 showing a marked clinical response in 78 patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had progressed during or after crizotinib therapy or had not been previously...

  More news about: Novartis , American Society of Clinical Oncology (ASCO)

• Jun 02, 2013, 09:00 ET

  Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor growth in women with HER2 positive advanced breast cancer

  Novartis today presented results from a pivotal Phase III trial of a treatment regimen including Afinitor® (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received prior taxane therapy and whose disease is...

  More news about: Novartis Oncology , Annual Meeting of the American Society of Clinical Oncology (ASCO)

• May 30, 2013, 01:15 ET

  Relapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC

   People with relapsing multiple sclerosis (MS) reported greater treatment satisfaction after starting the oral treatment Gilenya® (fingolimod) vs. switching to, or staying on, injectable interferon beta or glatiramer acetate, according to new study data presented at the 2013 Annual...

  More news about: Novartis Pharmaceuticals Corporation , Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC)

• May 29, 2013, 09:31 ET

  Critical Alerts For Novartis, Archer Daniels Midland, Whirlpool, Coach, and Dominos Pizza Released By InvestorsObserver

  

  InvestorsObserver issues critical PriceWatch Alerts for NVS, ADM, WHR, COH, and DPZ. (Photo: http://photos.prnewswire.com/prnh/20120712/CG39046) To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at...

  More news about: InvestorsObserver , Novartis , Archer Daniels Midland , Whirlpool , Coach , Dominos Pizza

• May 29, 2013, 01:21 ET

  Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA

   Novartis will present new findings in the treatment of advanced cancers and other diseases with 170 abstracts at two prominent medical meetings. Research across the extensive Novartis product portfolio and pipeline showcases the progress in advancing care for patients with cancer and...

  More news about: Novartis

• May 21, 2013, 07:15 ET

  Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement

  A new global survey sponsored by Novartis Oncology of nearly 1,300 women in 12 countries finds that despite breast cancer being the most common cancer in women worldwide, women living with advanced or metastatic breast cancer feel isolated and left out of the broader breast cancer movement. The...

  More news about: Novartis Oncology

• May 10, 2013, 01:20 ET

  Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis

   Novartis announced today that the US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older. Ilaris is the first interleukin-1 beta (IL-1 beta) inhibitor approved...

  More news about: Novartis Pharmaceuticals Corporation

• Apr 26, 2013, 18:52 ET

  Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts

   Novartis Pharmaceuticals Corporation (NPC) disputes the allegations made by the US Attorney's Office (USAO) for the Southern District of New York (SDNY) in two complaints filed this week and will defend itself in these litigations.  "We disagree with the way the government is...

  More news about: Novartis Pharmaceuticals Corporation

• Apr 25, 2013, 09:56 ET

  Novartis signs on to support Malaria No More's Power of One campaign to stride towards a future without malaria

   Novartis and Malaria No More, a leading global charity determined to end malaria deaths, announced today that they are joining forces on the Power of One campaign to help close the treatment gap and accelerate progress in the fight against malaria. Over the next three years, Novartis will...

  More news about: Novartis , Malaria No More , Power of One